1 / 11

Ntabeko Mpanza Richard Laing

Availability, Pricing and Affordability of Asthma Medicines 2001-2006 Presentation for Meeting on Availability, Pricing and Affordability of NCD Medicines WHO Geneva. Ntabeko Mpanza Richard Laing. Outline. Introduction & Background Methodology Results Availability Pricing

neona
Download Presentation

Ntabeko Mpanza Richard Laing

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Availability, Pricing and Affordability of Asthma Medicines 2001-2006Presentation for Meeting on Availability, Pricing and Affordability of NCD Medicines WHO Geneva Ntabeko Mpanza Richard Laing

  2. Outline • Introduction & Background • Methodology • Results • Availability • Pricing • Affordability • Discussion & Policy options

  3. Introduction & Background • Asthma was the 25th leading cause of disability adjusted life years lost worldwide in 2001, estimated to be about 15 million DALYs per year • Beclomethasone inhalers and salbutamol inhalers are on the WHO EML. • Recent paper in Allergy by N. Ait-Khaled, D. A. Enarson, K. Bissell, N. E. Billo. Access to inhaled corticosteroids is key to improving quality of care for asthma in developing countries. • However, many patients have difficulty accessing treatment; it is a challenge for them to get their medication and so, levels of uncontrolled asthma cases remain high. • Aim: Secondary analysis of price, availability and affordability of CVD medicines in 36 developing countries that have undertaken WHO/HAI surveys

  4. Methodology • WHO/HAI data • Standardized data collection • Prices as Median Price Ratios (MPRs) • Medicines: • Salbutamol 0.1mg/dose 200 dose inhalant • Beclomethasone 50ug/dose 200 dose inhalant • Secondary analysis • Adjustments for inflation and purchasing power • Analysis by World Bank Income Groups and WHO regions.

  5. Country list (48 surveys in 35 countries) Upper-middle income Brazil-Rio de Janeiro (2001) Kazakhstan (2004) Lebanon (2004) Malaysia (2004) South Africa - Kwazulu Natal (2001) High Income Kuwait (2004) United Arab Emirates (2006) Low income Chad Ethiopia (2004) Ghana (2004) India-Chennai (2004) India-Haryana (2004) India-Karnataka (2004) India-Maharashtra 12 districts (2004) India-Maharashtra 4 regions (2005) India-Rajasthan (2003) India-West Bengal Kenya (2004) Kyrgyzstan (2005) Mali (2004) Mongolia (2004) Nigeria (2004) Pakistan (2004) Sudan-Gadarif (2006) Sudan-Khartoum (2005) Sudan-Kordofan (2006) Tajikistan (2005) Tanzania (2004) Uganda (2004) Uzbekistan (2004) Yemen (2006) Lower-middle income Armenia (2001) Cameroon (2002) China-Shandong Province (2004) China-Shanghai (2006) El-Salvador (2006) Fiji (2004) Indonesia (2004) Jordan (2004) Morocco (2004) Peru (2005) Philippines (2005) Sri Lanka (2001) Syria (2003) Tunisia (2004)

  6. Results: Availability (%) Overall Availability of Beclomethasone and Salbutamol– WB Income Group Classifications Note: The numbers next to the income categories represent the number of countries that were found in the WHO HAI website

  7. Procurement and Patient PricesAdjusted for CPI and MSH prices

  8. Median Price Ratios of Beclomethasone and Salbutamol with surveys divided into Income Group categoriesAdjusted for CPI, MSH prices and PPP

  9. AffordabilityDays wages of Lowest Paid Government Worker • Note: • Average income often below lowest government wage • Need for multiple medicines

  10. Discussion & Policy options • Availability • Ensure availability of BOTH Beclo and salbutamol • Increase public sector funding for Asthma medicines • Procurement • Some countries: can improve on procurement prices possibly through ADF • Where procurement prices are good consider selling at cost to private sector or through patient associations • Patient prices • Lower taxes & tariffs • Promote the use of generics • Reduce mark-ups

  11. Thank you Please send any comments to:mpanzm@yahoo.com & laingr@who.int

More Related